This two-part webinar series explores the journey from academic research to securing investment and launching a successful NewCo.
Watch the Webinar
Please provide your details to gain access.
The Cell and Gene Therapy Catapult takes your data very seriously. By using this form you are consenting to the processing of your personal data as per ourprivacy policy.
Event Description
Whether you’re an early-stage founder, academic, or working within a technology transfer office (TTO), this series provides valuable insights into the process of spinning out companies from academic institutions.
In Part One of our webinar series, Maria Shutova, Senior Commercialisation of Research and Investment Manager at the Cell and Gene Therapy Catapult, will chair a discussion where panellists will highlight the key challenges, solutions, and practical insights for early-stage founders navigating the spin-out process. Topics will include the initial steps of spinning out, forming a viable business strategy, and overcoming obstacles in the transition from research to commercialization.
Panellists:
- Omer Dushek, Co-founder, MatchBio and Professor of Molecular Immunology, University of Oxford
- Djordje Djordjevic, Co-founder and Chief Executive Officer, Plurify
- Andrew Wilson, Head of Research Commercialisation, University of Bristol
- Terri Gaskell, Chief Technical Officer, Rinri Therapeutics
Who Should Attend?
- Academics and researchers considering or currently working on spinning out companies from their research.
- Early-stage founders seeking to understand the path from innovation to investment and market launch.
- Technology Transfer Office (TTO) professionals focused on supporting academic spin-outs.
- Investors and stakeholders interested in the unique challenges of academic spin-out companies.
Attendees will gain a comprehensive understanding of the distinct challenges in spinning out companies from academic settings, from securing funding to building partnerships and scaling their business.